{
    "clinical_study": {
        "@rank": "72267", 
        "arm_group": [
            {
                "arm_group_label": "NX-1207", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a  placebo QD oral treatment for 12 months."
            }, 
            {
                "arm_group_label": "Comparator", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the this international, multicenter, randomised, single-blind, parallel\n      group, Phase III study is to demonstrate that a single transrectal ultrasound (TRUS)-guided\n      intraprostatic injection of NX-1207 provides a long lasting therapeutic improvement of Lower\n      Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) in patients\n      not adequately controlled by medical therapy with \u03b1-blockers, as assessed by a change from\n      baseline in the International Prostate Symptom Score (IPSS) total score."
        }, 
        "brief_title": "Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH", 
        "condition": "Lower Urinary Tract Symptoms", 
        "condition_browse": {
            "mesh_term": "Prostatic Hyperplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent;\n\n          -  Age 45 or older;\n\n          -  Medical history of LUTS/BPH\n\n          -  Use of a marketed \u03b1-blocker for LUTS/BPH in the last 8 weeks;\n\n          -  LUTS/BPH not adequately controlled by medical therapy with \u03b1-blockers;\n\n          -  Presence of moderate-severe LUTS (IPSS \u2265 15) at screening and at baseline (after a 4\n             week run-in period with tamsulosin 0.4 mg QD);\n\n          -  Prostate Volume \u2265 30 mL and \u2264 70 mL (as assessed by TRUS);\n\n          -  Qmax < 15 mL/sec based on a minimum void of 125 mL;\n\n          -  Agree not to use any other approved or experimental BPH or overactive bladder (OAB)\n             medication anytime during the core study;\n\n          -  Agree to perform follow-up visits even in case of oral treatment discontinuation\n             before study end;\n\n          -  Satisfactory compliance to run-in medication at Visit 2 (baseline).\n\n        Exclusion Criteria:\n\n          -  Previous surgical or invasive prostate treatments such as TURP, TUMT, TUNA, laser or\n             any other minimally invasive treatment;\n\n          -  Acute or chronic prostatitis or suspected prostatitis including chronic pain,\n             intermittent pain or abnormal sensation in the penis, testis, anal or pelvic area in\n             the past 12 months;\n\n          -  PSA \u2265 10 ng/mL. In case of a PSA between 4.0 and 10.0 ng/mL, prostate cancer must\n             have been ruled out to the satisfaction of the clinical Investigator by an historical\n             biopsy;\n\n          -  Prostate or bladder cancer, history of pelvic irradiation;\n\n          -  Active or recurrent urinary tract infections (more than 1 episode in the last 12\n             months);\n\n          -  History of neurogenic bladder or LUTS secondary to neurologic disease;\n\n          -  Use of self-catheterization for urinary retention;\n\n          -  Post-void residual urine volume > 200 mL;\n\n          -  Haematuria which has not been appropriately evaluated to determine safe subject\n             participation;\n\n          -  Renal insufficiency (serum creatinine >2.0 mg/dL);\n\n          -  Liver insufficiency (any liver function tests [LFTs]>2x upper limit of normal [ULN]);\n\n          -  Poorly controlled diabetes (type 1 or type 2), as determined by HbA1c >6% and/or\n             glycosuria;\n\n          -  Any bleeding disorder such as haemophilia, clotting factor(s) deficiency or bleeding\n             diathesis;\n\n          -  Immunosuppressive disorders, such as Human Immunodeficiency (HIV) Virus, Acquired\n             Immune Deficiency Syndrome (AIDS), lymphoproliferative disorders;\n\n          -  Acute or chronic intestinal disease, such as ulcerative colitis, Crohn's disease,\n             acute gastroenteritis in the run-in period; acute painful perianal disorder;\n\n          -  Unstable cardiovascular or cerebrovascular disease (including acute myocardial\n             infarction, unstable angina pectoris, by-pass, Percutaneous Transluminal Coronary\n             Angioplasty (PTCA), congestive heart failure NYHA Class III-IV, stroke, transient\n             ischemic attack and episodes of cardiac arrhythmia requiring treatment in the last 6\n             months);\n\n          -  Any condition that would interfere with the subject's ability to provide informed\n             consent, to comply with study instructions, or that might confound the interpretation\n             of the study results, such as dementia, psychosis, manic depressive disorder,\n             post-traumatic stress disorder, stroke, Alzheimer's, depression, psychiatric illness,\n             history or current evidence of drug or alcohol abuse within the last 12 months etc.;\n\n          -  Participation in a study of any investigational drug or device within the previous 6\n             months;\n\n          -  Hypersensitivity or contraindication to tamsulosin use;\n\n          -  Use of prohibited medications that could endanger subjects performing the\n             intraprostatic injection or that could interfere with the evaluation of study\n             parameters;\n\n          -  Men planning to have children in the future;\n\n          -  Any other condition that may interfere with the study or endanger the subject."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003742", 
            "org_study_id": "NX1207-IT-CL 0414"
        }, 
        "intervention": [
            {
                "arm_group_label": "NX-1207", 
                "description": "Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207", 
                "intervention_name": "NX-1207", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Comparator", 
                "description": "1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD", 
                "intervention_name": "Tamsulosin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tamsulosin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "LUTS", 
            "BPH"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Christian GRATZKE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "Klinikum der Ludwig-Maximilians-universit\u00e4t M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Christian GRATZKE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20132"
                    }, 
                    "name": "Vita e Salute University, Department of Urology, Istituto Scientifico Ospedale San Raffaele"
                }, 
                "investigator": {
                    "last_name": "Francesco Montorsi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Piotr Humanski, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Kutno", 
                        "country": "Poland", 
                        "zip": "99-300"
                    }, 
                    "name": "Niepubliczny Zaklad Opieki Zdrowotnej Specjalista"
                }, 
                "investigator": {
                    "last_name": "Piotr Humanski, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Carlos HERN\u00c1NDEZ FERN\u00c1NDEZ, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Carlos HERN\u00c1NDEZ FERN\u00c1NDEZ, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "c.r.chapple@sheffield.ac.uk", 
                    "last_name": "Christopher Re Chapple, BSc MD", 
                    "phone": "+44 07768902102"
                }, 
                "contact_backup": {
                    "email": "susannah.hulton@sth.nhs.uk", 
                    "last_name": "Susannah Hulton, RGN", 
                    "phone": "+44 0114 2711870"
                }, 
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "zip": "S10 2JF"
                    }, 
                    "name": "Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital"
                }, 
                "investigator": {
                    "last_name": "Christopher Re Chapple, Bsc MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Poland", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of a Single Transrectal Ultrasound(TRUS)-Guided Intraprostatic Injection of NX-1207 in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Phase III European Study", 
        "other_outcome": {
            "description": "The following data will be evaluated:\nPercentage of subjects requiring medical therapy, MIST, TURP or surgery for LUTS/BPH and time to treatment failure;\nChange from baseline in the total score of the IPSS;\nChange from baseline in QoL due to urinary symptoms\nChange from baseline in general health-related QoL (EQ-5D-5L);\nSAEs and episodes of acute urinary retention.", 
            "measure": "Long term follow-up evaluation", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "overall_contact": {
            "email": "miotto.f@recordati.it", 
            "last_name": "Federica Miotto", 
            "phone": "+39.02.48787183"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy parameter is the change from baseline in the total score (Questions 1 to 7) of the IPSS at 12 months.\nThe IPSS questionnaire will be filled by the subjects in blind conditions and will be reviewed by the investigators for its completeness. Validated local translations of the IPSS questionnaire will be used in each country.", 
            "measure": "Change from baseline in the total IPSS score.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003742"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in IPSS total score at 1, 3, 6 and 9 months;\nChange from baseline in IPSS subscores for storage symptoms;\nChange from baseline in IPSS subscores for voiding symptoms;\nResponse rate by IPSS", 
                "measure": "Effects on Lower Urinary Tract Symptoms", 
                "safety_issue": "No", 
                "time_frame": "1,3,6,9 and 12 months"
            }, 
            {
                "description": "Change from baseline in IPSS subscore Quality of Life due to urinary symptoms;\nChange from baseline in BPH Impact Index", 
                "measure": "Effects on Quality of Life (QoL) due to urinary symptoms", 
                "safety_issue": "No", 
                "time_frame": "1,3,6,9 and 12 months"
            }, 
            {
                "description": "The change from baseline in the EQ-5D-5L questionnaire at 12 months or in case of early termination will be considered.\nThe EQ-5D-5L questionnaire is a standardised validated instrument for use as a measure of health outcome.", 
                "measure": "Effects on general health related Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "A patient-rated global assessment of treatment benefit, satisfaction and willingness to continue will be performed at 12 months (or in case of early termination) by using the BSW questionnaire.\nThe BSW is a validated questionnaire that consists of three, single-item measures designed to capture the patient's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.", 
                "measure": "Patient's global assessment of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To evaluate the effect on urinary flow, the change from baseline in maximum urinary flow (Qmax) at 3, 6, 9, 12 months will be considered. The same validated device and procedure will be used in all centres and a blinded centralized reading is foreseen.", 
                "measure": "Effects on maximum urinary flow rate (Qmax)", 
                "safety_issue": "No", 
                "time_frame": "3,6,9 and 12 months"
            }, 
            {
                "description": "The change from baseline in TRUS assessed prostate volume at 3 and 12 months (or in case of early termination) will be considered.", 
                "measure": "Effects on prostate volume", 
                "safety_issue": "No", 
                "time_frame": "3 and 12 months"
            }
        ], 
        "source": "Recordati Industria Chimica e Farmaceutica S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Recordati Industria Chimica e Farmaceutica S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}